HOUSTON--(BUSINESS WIRE)--Feb. 19, 2004--Lark Technologies Inc. (OTCBB:LRKT - News) announced today that the Securities and Exchange Commission has declared the registration statement on Form S-4 containing the joint proxy statement/prospectus for the proposed merger of Lark Technologies Inc. with a subsidiary of Genaissance Pharmaceuticals Inc. effective as of Feb. 17, 2004. A special meeting at which Lark stockholders will vote on the merger with Genaissance has been scheduled for April 1, 2004 at 9 a.m. at the company's offices in Houston, Texas. A prospectus and proxy will be sent to all Lark stockholders of record as of Feb. 17, 2004.
Investors and security holders are urged to read the joint proxy statement/prospectus regarding the proposed merger, which contains important information about the transaction. Investors and security holders may obtain a copy of the joint proxy statement/prospectus and other documents filed by Genaissance and Lark with the SEC free of charge at the SEC's Web site at http://www.sec.gov or at the public reference facilities maintained by the SEC at: Judiciary Plaza, Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549. In addition, investors and security holders are able to obtain free copies of the registration statement and the joint proxy statement/prospectus from Lark by contacting Ms. Theresa Grider at 713-779-3663, extension 100.
Lark and its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement. Information regarding the special interests of the directors and executive officers of Lark in the transaction described herein is included in the joint proxy statement/prospectus.
Lark Technologies Inc., based in Houston, Texas, offers genomic services for use in pharmaceutical, diagnostic and agricultural product research and development. These services include genomic data management, microarray support, quantitative PCR, genotyping, genetically modified organism testing and a battery of other molecular biology services which support researchers in the pharmaceutical, biotechnology and academic sectors in their attempt to understand the mechanisms of disease and to discover and develop new drugs. Lark's stock is quoted on the OTC Bulletin Board under the symbol "LRKT.OB." Visit the company's Web site at www.lark.com.
Genaissance Pharmaceuticals Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Conn. Visit the company's Web site at www.Genaissance.com.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These forward-looking statements speak only as of the date hereof. Lark disclaims any intent or obligation to update these forward-looking statements.
Lark Technologies Inc., Houston Carl W. Balezentis, 713-779-3663 Ext. 134
Source: Lark Technologies Inc.